Latest Safety News

Alpha HPA Limited reports a surge in semiconductor sector demand driven by AI infrastructure expansion, with significant upgrades in Letters of Intent from key Japanese customers and ongoing capacity expansion.

Etherstack plc has secured a significant revenue uplift from a scope change in its primary UK government project, adding £1.53 million to its future earnings forecast for FY27.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

Amplia Therapeutics reports a remarkable 7.8% complete response rate and improved survival in its ACCENT pancreatic cancer trial, positioning narmafotinib as a promising new treatment option.

Lindian Resources has operationalised its Tipume Accommodation Camp at the Kangankunde Rare Earths Project, enabling workforce expansion and accelerating construction towards first production in late 2026.

ABx Group’s mixed rare earth carbonate from Tasmania’s Deep Leads project has earned strong validation from US-based Rare Earth Technologies Inc, confirming its high purity and compatibility with cutting-edge separation technology.

Finder Energy has confirmed the technical feasibility of repurposing the Petrojarl I FPSO vessel for its Kuda Tasi and Jahal oil fields, setting the stage for a final investment decision by mid-2026.

Nexalis Therapeutics has initiated dosing in its Phase 1 trial of IRX-616a, a novel cannabidiol inhalation treatment targeting panic disorder. The trial aims to evaluate safety and pharmacokinetics, with dose escalation decisions expected soon.

Imricor Medical Systems has filed a Form 10 registration with the U.S. SEC, marking its transition to a U.S. reporting company amid ongoing FDA clearances and clinical trials. This move signals a significant step in its early commercialisation of MRI-guided cardiac ablation technology.

Immutep Limited has successfully completed the single ascending dose phase of its IMP761 trial, showing promising safety and immunosuppressive effects in healthy volunteers. The biotech’s novel LAG-3 agonist could reshape autoimmune disease treatment.

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

Western Gold Resources has formalised critical road access agreements enabling ore haulage from its Gold Duke Project to nearby processing facilities, marking a significant step forward in project development.